Access to Vorasidenib for the Treatment of Glioma

Full Title

Vorasidenib Expanded Access Protocol in Patients with IDH1 or IDH2 Mutated Glioma (EAP)

Purpose

This study is providing access to the drug vorasidenib for people with brain cancer. The people in this study have glioma with a mutation (change) in the IDH1 or IDH2 gene. This mutation can cause cancer cells to multiply and spread.

Vorasidenib acts directly on the IDH proteins that contribute to cancer growth and survival. By blocking these proteins, vorasidenib may help slow or stop the growth of your cancer. Vorasidenib is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have oligodendroglioma or astrocytoma with an IDH1 or IDH2 mutation.
• Have had prior surgery for glioma (including biopsy).
• Be age 12 or older.

Contact

For more information or to see if you can join this study, please call 212-610-0261. You may also call Dr. Thomas Kaley’s office at 212-639-5122.